AR091977A1 - El uso de antitrombina en la oxigenacion de membranas extracorporeas - Google Patents
El uso de antitrombina en la oxigenacion de membranas extracorporeasInfo
- Publication number
- AR091977A1 AR091977A1 ARP130102756A ARP130102756A AR091977A1 AR 091977 A1 AR091977 A1 AR 091977A1 AR P130102756 A ARP130102756 A AR P130102756A AR P130102756 A ARP130102756 A AR P130102756A AR 091977 A1 AR091977 A1 AR 091977A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxygenation
- extracorpore
- antitrombin
- membranes
- antithrombin
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title 1
- 238000006213 oxygenation reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000004019 antithrombin Substances 0.000 abstract 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 229940089003 atryn Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Métodos para la supresión de la coagulación de la sangre y/o la prevención de la hemorragia en un sujeto que recibe oxigenación por membrana extracorpórea que comprende la administración de antitrombina. En algunas formas de realización, la antitrombina que se utiliza en los métodos descritos en el presente documente es ATryn®. Reivindicación 10: El método de una cualquiera de las reivindicaciones 1 - 8, en donde la antitrombina se administra a una dosis de 295 unidades por kg. Reivindicación 14: El método de una cualquiera de las reivindicaciones 1 - 13, que comprende además la administración de heparina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679345P | 2012-08-03 | 2012-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091977A1 true AR091977A1 (es) | 2015-03-11 |
Family
ID=50028554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102756A AR091977A1 (es) | 2012-08-03 | 2013-08-02 | El uso de antitrombina en la oxigenacion de membranas extracorporeas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9511087B2 (es) |
| EP (1) | EP2879697A4 (es) |
| JP (1) | JP6389172B2 (es) |
| KR (1) | KR20150039201A (es) |
| CN (1) | CN104884080A (es) |
| AR (1) | AR091977A1 (es) |
| AU (1) | AU2013296240B2 (es) |
| BR (1) | BR112015002321A2 (es) |
| CA (1) | CA2879763C (es) |
| IL (1) | IL236776A0 (es) |
| MX (1) | MX2015001508A (es) |
| TW (1) | TW201425332A (es) |
| WO (1) | WO2014022748A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090067A1 (en) | 2010-12-30 | 2012-07-05 | Lfb Biotechnologies | Glycols as pathogen inactivating agents |
| WO2014022748A1 (en) | 2012-08-03 | 2014-02-06 | Revo Biologics, Inc. | The use of antithrombin in extracorporeal membrane oxygenation |
| WO2014140927A2 (en) | 2013-02-13 | 2014-09-18 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US10174110B2 (en) | 2013-02-13 | 2019-01-08 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-α antibodies and uses thereof |
| KR20160029840A (ko) | 2013-07-05 | 2016-03-15 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 친화성 크로마토그래피 매트릭스 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3388140A1 (en) * | 2017-04-10 | 2018-10-17 | Gambro Lundia AB | Extracorporeal blood circuit |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
| US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
| US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| DE4028800A1 (de) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
| DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5801063A (en) * | 1995-05-09 | 1998-09-01 | Grandics; Peter | Device and process for the biospecific removal of heparin |
| US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| JP2001512976A (ja) | 1997-02-25 | 2001-08-28 | ジェンザイム・トランスジェニックス・コーポレーション | トランスジェニックにより産生された非分泌性タンパク質 |
| US20060264357A1 (en) | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
| US8257724B2 (en) | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| DE10159556A1 (de) | 2001-12-05 | 2003-06-12 | Aventis Behring Gmbh Intellect | Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen |
| SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| EP1670931A2 (en) | 2003-09-05 | 2006-06-21 | GTC Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| CA2479968A1 (en) | 2004-09-01 | 2006-03-01 | Keith R. Walley | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
| CA2572179A1 (en) | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| EP1913155A4 (en) | 2005-06-23 | 2009-08-12 | Univ British Columbia | COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY |
| US20070037192A1 (en) | 2005-07-25 | 2007-02-15 | Gtc Biotherapeutics, Inc. | Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile |
| KR101507027B1 (ko) | 2005-10-21 | 2015-03-31 | 엘에프비 유에스에이, 인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법 |
| US20070292407A1 (en) | 2005-12-12 | 2007-12-20 | The Board Of Trustees Operating Michigan State University | Methods of treatment for meconium aspiration syndrome |
| US7531632B2 (en) | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| WO2007124019A2 (en) | 2006-04-21 | 2007-11-01 | Gtc Biotherapeutics, Inc. | Methods and products related to the transfer of molecules from blood to the mammary gland |
| WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US20110082083A1 (en) | 2009-04-10 | 2011-04-07 | Gtc Biotherapeutics, Inc. | Formulations of liquid stable antithrombin |
| US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
| JP6178311B2 (ja) | 2011-07-07 | 2017-08-09 | エルエフビー ユーエスエー インコーポレイテッドＬｆｂ Ｕｓａ， Ｉｎｃ． | タンパク質を安定化する製剤 |
| TW201400499A (zh) | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
| WO2014022748A1 (en) | 2012-08-03 | 2014-02-06 | Revo Biologics, Inc. | The use of antithrombin in extracorporeal membrane oxygenation |
-
2013
- 2013-08-02 WO PCT/US2013/053365 patent/WO2014022748A1/en not_active Ceased
- 2013-08-02 KR KR1020157002667A patent/KR20150039201A/ko not_active Ceased
- 2013-08-02 CA CA2879763A patent/CA2879763C/en active Active
- 2013-08-02 MX MX2015001508A patent/MX2015001508A/es unknown
- 2013-08-02 CN CN201380041286.1A patent/CN104884080A/zh active Pending
- 2013-08-02 AU AU2013296240A patent/AU2013296240B2/en not_active Ceased
- 2013-08-02 BR BR112015002321A patent/BR112015002321A2/pt not_active IP Right Cessation
- 2013-08-02 US US14/239,943 patent/US9511087B2/en not_active Expired - Fee Related
- 2013-08-02 TW TW102127828A patent/TW201425332A/zh unknown
- 2013-08-02 JP JP2015525617A patent/JP6389172B2/ja not_active Expired - Fee Related
- 2013-08-02 EP EP13825397.6A patent/EP2879697A4/en not_active Withdrawn
- 2013-08-02 AR ARP130102756A patent/AR091977A1/es unknown
-
2015
- 2015-01-18 IL IL236776A patent/IL236776A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015002321A2 (pt) | 2019-10-22 |
| TW201425332A (zh) | 2014-07-01 |
| EP2879697A1 (en) | 2015-06-10 |
| MX2015001508A (es) | 2015-04-08 |
| JP6389172B2 (ja) | 2018-09-12 |
| EP2879697A4 (en) | 2016-01-20 |
| WO2014022748A1 (en) | 2014-02-06 |
| US9511087B2 (en) | 2016-12-06 |
| AU2013296240B2 (en) | 2018-05-17 |
| KR20150039201A (ko) | 2015-04-09 |
| CA2879763C (en) | 2020-12-01 |
| JP2015524823A (ja) | 2015-08-27 |
| US20140194360A1 (en) | 2014-07-10 |
| CA2879763A1 (en) | 2014-02-06 |
| CN104884080A (zh) | 2015-09-02 |
| IL236776A0 (en) | 2015-03-31 |
| AU2013296240A1 (en) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091977A1 (es) | El uso de antitrombina en la oxigenacion de membranas extracorporeas | |
| MX2021001867A (es) | Administracion y monitoreo de oxidio nitrico en fluidos ex vivo. | |
| MX2022001442A (es) | Sistemas, dispositivos y metodos relacionados con guia de dosis de medicamentos. | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CR20170279A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| CL2012003038A1 (es) | Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia. | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| BR112016010103A8 (pt) | métodos, kits e dispositivos de suprimento de fármaco osmótico. | |
| BR112014026616A2 (pt) | dialisado à base de polímero | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
| CL2015002747A1 (es) | Metodo para la oxigenacion extracorporea de un sujeto; y aparato de incubacion. | |
| DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| BR112016026243A2 (pt) | membrana, molécula de fibra oca, uso de uma membrana, e, copolímero em bloco | |
| CL2013001382A1 (es) | Metodo para aumentar la seguridad y la eficacia de las transfusiones de sangre, que comprende administrar a un paciente una composicion farmaceutica que comprende un copolimero de polioxietileno/polioxipropileno, en donde la composicion se mezcla con la sangre antes de la transfusion, o se administra al paciente antes o despues de la transfusion. | |
| GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| BR112014014869A2 (pt) | derivados de sulfonilaminopirrolidinona, sua preparação e sua aplicação terapêutica | |
| ECSP10010553A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| CO2018000768A2 (es) | Administración intravenosa de citrulina durante la cirugía | |
| CL2015001943A1 (es) | Derivados de bencilamina | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
| UA112488C2 (uk) | Три(гетеро)арилпіразоли і їх застосування | |
| BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
| MX2017014731A (es) | Eliminacion de linfocitos b como marcador diagnostico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |